Cargando…
Durable remission related to CAR-T persistence in R/R B-ALL and long-term persistence potential of prime CAR-T
CD19-targeted chimeric antigen receptor T lymphocytes (CAR-T) has demonstrated a high proportion of complete remission in the treatment of relapsed refractory acute B cell lymphoblastic leukemia (r/r B-ALL). It is of great clinical significance to explore which factors will impact long-term disease-...
Autores principales: | Shiqi, Li, Jiasi, Zhang, Lvzhe, Chen, Huailong, Xu, Liping, He, Lin, Liu, Qianzhen, Zhang, Zhongtao, Yuan, Junjie, Shen, Zucong, Chen, Yingzi, Zhang, Meiling, Wang, Yunyan, Li, Linling, Wang, Lihua, Fang, Yingnian, Chen, Wei, Zhu, Yu, Li, Le, Luo, Youcheng, Wang, Dingsong, Zhang, Yancheng, Dong, Ping, Yin, Lihua, Zhang, Xiaoping, Li, Xiaozhuang, Hu, Zhongzheng, Zheng, Zhi, Yang, Cheng, Qian, Sanbin, Wang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10196916/ https://www.ncbi.nlm.nih.gov/pubmed/37215385 http://dx.doi.org/10.1016/j.omto.2023.04.003 |
Ejemplares similares
-
Strategies to enhance CAR-T persistence
por: Liu, Yue, et al.
Publicado: (2022) -
Improving CAR T-Cell Persistence
por: Pietrobon, Violena, et al.
Publicado: (2021) -
PD-1 abrogates the prolonged persistence of CD8(+) CAR-T cells with 4-1BB co-stimulation
por: Li, Feng, et al.
Publicado: (2020) -
CRISPR/Cas9: A Powerful Strategy to Improve CAR-T Cell Persistence
por: Wei, Wei, et al.
Publicado: (2023) -
CAR-T Cell Performance: How to Improve Their Persistence?
por: López-Cantillo, Gina, et al.
Publicado: (2022)